Müller C, et al. - Given the significance of time to treatment onset (TTTO) in breast cancer patients receiving neoadjuvant chemotherapy (NACT), researchers sought for the possible delaying factors of therapy onset. Among 139 analyzed patients [average age: 53 years (±13.2 years)] who were scheduled for NACT, 90 (64.7%) received standard NACT, and 49 (35.3%) were recruited for trials. Between diagnosis and therapy onset, they noted a time interval of 30.7 days (±11.8 days). The outpatient presentation and the inpatient presentation extended the time interval by 2 days and 4 days, respectively. They recommend merging these presentations in order to lessen TTTO. No delay in therapy onset was observed in relation to either the site of pathology examinations, additional consultations (genetics, reproductive medicine), or study participation.